Objective:

To assess the efficacy and safety of tiragolumab plus atezolizumab plus chemotherapy compared with standard-of-care pembrolizumab plus chemotherapy in patients with advanced or metastatic nonsquamous NSCLC.

Approach:

Key Findings:

• The study met prespecified thresholds for progression-free survival, allowing for phase 3 enrollment.

Interpretation:

The combination of anti-TIGIT and anti-PD-L1 therapies in conjunction with chemotherapy represents a potential strategy to improve treatment outcomes in advanced nonsquamous NSCLC.

Limitations:

• Several major anti-TIGIT programs have been discontinued despite initial promise.
• The study's results may not be generalizable to all NSCLC patient populations.

Conclusion:

The SKYSCRAPER-06 trial assessed the efficacy of combining tiragolumab with atezolizumab and chemotherapy in advanced nonsquamous NSCLC.

Source

Based on findings from:

Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non–Small Cell Lung Cancer: The Phase

Mark A. Socinski, Rolf Stahel, Dae Ho Lee, Federico Cappuzzo, Makoto Nishio, Christine M. Lovly, Ozgur Ozyilkan, Qingshan Li, Melissa Johnson, Edward B. Garon, Saadettin Kilickap, Flavio Augusto Ferreira da Silva, Jorge Alatorre-Alexander, Raymond Meng, Reena Amin, Christina Matheny, Sarah Troutman, Xiaohui Wen, Namrata S. Patil, Wei Zou, Delvys Rodriguez-Abreu. Jama Oncology, 2026.

https://jamanetwork.com/journals/jamaoncology/fullarticle/2848246

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.